French pharmaceutical company Sanofi has announced that it is discontinuing development of its mRNA-based seasonal influenza vaccine – despite investing $3.2 billion in mRNA technology as recently as 2021. The announcement comes amid a turbulent period for the vaccine industry in the United States, where Health Secretary Robert F. Kennedy Jr. has withdr…